The Majority of Autologous Cytolytic T-lymphocyte Clones Derived From Peripheral Blood Lymphocytes of a Melanoma Patient Recognize an Antigenic Peptide Derived From Gene Pmel17/gp100

J Invest Dermatol. 1996 Jul;107(1):63-7. doi: 10.1111/1523-1747.ep12298177.

Abstract

Anti-melanoma cytolytic T-lymphocyte (CTL) clones were derived from peripheral blood lymphocytes of HLA-A2 melanoma patient LB265 after stimulation with the autologous tumor cell line LB265-MEL, which showed high expression of melanocyte-lineage specific genes. Of 55 CTL clones, 46 recognized HLA-A2-restricted antigens. These 46 CTL clones were studied for their ability to specifically release tumor necrosis factor in the presence of COS cells cotransfected with the HLA-A2 gene and the cDNA of either tyrosinase, Melan-A/MART1, Pmel17/gpl00, gp75/TRP1, or MSH receptor. Six CTL clones recognized the Melan-A/MART1 antigen, whereas the remaining 40 CTL clones recognized a Pmel17/gp100 antigen. These 40 anti-PmelI7/gpl00 CTL clones were all able to lyse T2 cells pulsed with the antigenic peptide YLEPGPVTA, as previously reported. The T-cell receptor beta chain hypervariable region was sequenced and found to be identical in the 15 CTL clones analyzed. Taken together, these data show a high frequency of Pmell7/gp100-specific T cells in autologous antitumor CTL clones derived from peripheral blood of a melanoma patient.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Antigens, Neoplasm / immunology*
  • Base Sequence
  • Clone Cells
  • Female
  • Genes*
  • HLA-A2 Antigen / genetics*
  • Humans
  • Melanoma / blood
  • Melanoma / immunology*
  • Molecular Sequence Data
  • Oligonucleotide Probes / genetics
  • Receptors, Antigen, T-Cell, alpha-beta / genetics
  • T-Lymphocytes, Cytotoxic / immunology*

Substances

  • Antigens, Neoplasm
  • HLA-A2 Antigen
  • Oligonucleotide Probes
  • Receptors, Antigen, T-Cell, alpha-beta